Substack · Phaetrix Investing · Phaetrix
Eli Lilly Reassessed: Earned Part of the Rally, Still a Hold
The business delivered more than I expected. Now Lilly has to prove its metabolic platform can justify a trillion-dollar valuation.
Since publication +3.1% α +3.3 pp vs S&P 500 · USD